KKR will invest $65M in China Cord Blood (CO +22.2%), the country’s largest operator of services...


KKR will invest $65M in China Cord Blood (CO +22.2%), the country’s largest operator of services for umbilical cord blood that is rich in stem cells, to capitalize on China’s fast growing healthcare services industry. As share prices of U.S.-listed Chinese companies take a beating, some PE firms sniff opportunities.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs